Calistoga Pharmaceuticals Announces Two Oral Presentations on CAL-101 at 51st American Society of Hematology (ASH) Annual Meeting

Clinical Response Data in Patients with Hematologic Malignancies and Preclinical Data Supporting Role of CAL-101 as Potent, Isoform-Selective PI3K Inhibitor


 

SEATTLE--(BUSINESS WIRE)--Dec 1, 2009 - Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.


 

CAL-101 oral presentations at the ASH meeting include:


 

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, an Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies


 


  • Presenter: Ian W Flinn, M.D., Ph.D., Director of Hematologic Malignancies Research at the Sarah Cannon Research Institute, Nashville, TN.
     
  • Tuesday, December 8, 2009, 8:15 a.m., Ernest N. Morial Convention Center, Room 260-262
     
  • Oral Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments
     
  • Abstract #922: http://ash.confex.com/ash/2009/webprogram/Paper23760.html
     


 

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment


 

 


 


  • Presenter: Brian Lannutti, Ph.D., Calistoga Pharmaceuticals
     
  • Monday, December 7, 2009, 7:45 a.m., Ernest N. Morial Convention Center, Room 243-245
     
  • Oral Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Novel Small Molecule Inhibitors In Preclinical Lymphoma Models
     
  • Abstract #286: http://ash.confex.com/ash/2009/webprogram/Paper21880.html
     


 

CAL-101 is a potent inhibitor of PI3K p110δ (delta) with 40- to 300-fold selectivity for the delta isoform as compared to other PI3K isoforms. CAL-101 is being evaluated in an ongoing Phase 1 trial in patients with relapsed or refractory chronic lymphocytic leukemia, B-cell non-Hodgkin's lymphoma, acute myeloid leukemia, or multiple myeloma. Observations of clinical responses from this trial have been previously reported. In preclinical efficacy studies, CAL-101 demonstrated inhibition of the PI3K pathway, decreases in cellular proliferation, and/or cell death for multiple B cell malignancies including CLL and NHL providing preclinical validation of PI3K delta inhibition for the treatment of these diseases.


 

About Calistoga Pharmaceuticals


 

Calistoga Pharmaceuticals is dedicated to developing innovative medicines targeting selective isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting isoforms of the PI3K pathway. The Company's most advanced compound, CAL-101, a p110δ selective PI3K inhibitor, is under clinical evaluation in patients with hematologic malignancies. Calistoga is a private company headquartered in Seattle, Washington. For more information, visit the Company's website at: www.calistogapharma.com.


 

 


 

 


 

Contact: Rathbun Communications, Inc.

Julie Rathbun, 206-769-9219

Julie@rathbuncomm.com


 

 


 

 

Posted: December 2009

View comments

Hide
(web1)